Standard yearly blood work is not designed to detect cancer and will miss most cancers entirely. A complete blood count, metabolic panel, and liver function tests can occasionally flag abnormalities that turn out to be cancer-related, but these tests were built to monitor general health, not to screen for malignancy. The overlap between “normal variation” and “early cancer signal” is enormous, which means both false alarms and missed diagnoses are common. That said, the landscape is shifting: newer blood-based technologies are being developed specifically to catch cancer early, and researchers are finding ways to squeeze more predictive value out of the routine tests your doctor already orders.
What a Complete Blood Count Can and Cannot Show
The complete blood count, or CBC, is the single most commonly ordered blood test in medicine. It measures your red blood cells, white blood cells, and platelets. Because those cells are produced in bone marrow, a CBC can sometimes catch blood cancers like leukemia, where abnormal cells crowd out normal ones and cause counts to spike or plummet in ways that are hard to ignore.1PubMed Central. The Unintentional Detection of Leukemias with Complete Blood Count The key word there is “unintentionally.” Nobody orders a CBC expecting it to find leukemia. But when white blood cell counts come back wildly abnormal, that finding can trigger the workup that leads to a diagnosis.
For solid tumors, the CBC is far less useful. One large study found that people with very high platelet counts, those in the top tenth of the range, had roughly double the odds of being diagnosed with a solid cancer within six months compared to people with middle-of-the-road platelet counts. For certain cancers, the association was much stronger: the odds were about four times higher for colon, lung, ovarian, and stomach cancers.2PubMed Central. Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period That sounds dramatic, but it is important to keep perspective. Most people with high platelet counts do not have cancer. The signal fades quickly as you move further from the diagnosis date, which tells us cancer itself is probably driving the platelet rise rather than the other way around.
Researchers have also looked at whether trends in CBC values over time, rather than a single snapshot, could hint at colorectal cancer. In a UK primary care study, differences in red blood cell counts, hemoglobin, white blood cells, and platelets between people who were later diagnosed with colorectal cancer and matched controls became statistically apparent up to four years before diagnosis.3PubMed Central. Trends in the full blood count blood test and colorectal cancer detection: a longitudinal, case-control study of UK primary care patient data The differences were real, but they were also subtle enough that no single CBC result would raise a red flag. This is why several research groups are now trying to use machine learning to pick up patterns that a human eye would miss, a topic we will return to later.
What Your Metabolic Panel Might Reveal
A basic or comprehensive metabolic panel measures things like blood sugar, kidney function markers (creatinine, blood urea nitrogen), electrolytes, and sometimes liver enzymes. None of these are cancer tests. But cancer can affect organ function, and organ function markers occasionally become the first visible sign that something is wrong.
Liver enzymes are the most instructive example. In patients with hepatitis B, the liver enzyme GGT showed a strong independent association with later liver cancer, roughly two and a half times the risk even after accounting for the presence of cirrhosis.4PLoS ONE. Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients Other liver enzymes like AST and ALP were also linked to liver cancer, but their association disappeared once cirrhosis was factored in, meaning they were reflecting liver damage rather than cancer specifically. In breast cancer patients who later developed liver metastases, several liver function markers were already abnormal about six months before the metastases were formally detected.5PLoS ONE. Liver function indicators in patients with breast cancer before and after detection of hepatic metastases-a retrospective study That is useful for monitoring someone already diagnosed with cancer, but it would not help an otherwise healthy person catch a cancer that has not yet been found.
Alkaline phosphatase, or ALP, deserves a separate mention. It often appears on routine panels and can be elevated in both liver and bone disease. Patients with cancers that have spread to bone frequently show elevated ALP and calcium levels.6PubMed Central. Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer Again, this tends to show up when disease is already advanced, not in the early stages where screening would be most valuable.
Kidney function markers tell a similar story. Multiple myeloma, a blood cancer, frequently damages the kidneys. Elevated creatinine and abnormal kidney function are common findings at the time of myeloma diagnosis.7PubMed. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group A sudden, unexplained decline in kidney function in an older adult can prompt further investigation that leads to the diagnosis. But kidney function declines for many reasons, and myeloma is far down the list of likely causes.
Inflammatory Markers Are Suggestive, Not Diagnostic
Some yearly panels include inflammatory markers like C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). These measure how much inflammation is circulating in your body, and inflammation is involved in the development of many cancers. A large prospective study in UK primary care found that people with a raised inflammatory marker had a cancer incidence of about 3.5% within a year, compared to 1.5% in those with normal results and under 1% in people who were not tested at all.8PubMed Central. Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records There was a clear dose-response relationship: the higher the inflammatory marker, the greater the chance of cancer. Among people with ESR values above 100, roughly one in seven was diagnosed with cancer within a year.
Those numbers sound alarming, but context matters. Even in the highest-risk group, most people did not have cancer. And inflammatory markers rise for dozens of reasons, from infections to autoimmune conditions to simple aging. A study of over 84,000 people in the general population found that simultaneously elevated CRP, fibrinogen, and white blood cell count were associated with increased risk of colorectal, lung, and breast cancer, though the researchers concluded the cancer itself was likely driving the inflammation rather than chronic low-grade inflammation causing the cancer.9PubMed. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population In other words, by the time inflammation shows up in your blood, the cancer may already be established. The inflammatory marker is a late signal, not an early warning.
Tumor Markers Your Doctor Might Order
Beyond routine panels, some doctors order specific tumor markers. The two most discussed in primary care are PSA for prostate cancer and CEA for colorectal cancer. Both illustrate why using blood tests for cancer screening is harder than it sounds.
PSA screening has been debated for decades. One major trial found no reduction in prostate cancer death after 13 years of follow-up in the screening group, while a European trial found that screening did reduce prostate cancer death but required 37 additional men to be diagnosed through screening for every one death prevented.10JAMA. Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence That imbalance means many men are diagnosed with and treated for cancers that would never have caused symptoms in their lifetime. The harms of overdiagnosis, including anxiety, biopsies, surgery, and side effects like incontinence and erectile dysfunction, are real and well documented.
CEA, or carcinoembryonic antigen, is sometimes checked in people at higher risk for colorectal cancer. Using a standard cutoff, CEA only detects about one in four colorectal cancers up to a year before clinical diagnosis. Lowering the threshold picks up a few more cancers but also dramatically increases the number of false positives, sending about one in seven healthy people for unnecessary colonoscopies. Researchers have concluded that CEA alone has little use for screening in the general population.11British Journal of Cancer. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples CEA is more commonly used to monitor people who have already been treated for colorectal cancer to watch for recurrence.
How Blood Tests Help When Symptoms Are Already Present
Where routine blood work genuinely earns its keep is not in screening healthy people but in evaluating people who already have vague symptoms. A large English study of nearly half a million primary care patients with nonspecific abdominal symptoms found that incorporating blood test results into clinical decision-making meaningfully improved cancer detection. For every 1,000 patients with abdominal bloating who had blood tests, about five additional cancer patients were identified for urgent referral compared to relying on symptoms, age, and sex alone.12PLOS Medicine. Predictive value of abnormal blood tests for detecting cancer in primary care patients with nonspecific abdominal symptoms Five out of 1,000 may not sound like much, but for those five people, the earlier referral could be life-changing. The lesson is that blood tests are most powerful not as standalone screening tools but as additional evidence layered onto the clinical picture your doctor is already assembling.
Multi-Cancer Early Detection Tests
The most significant development in blood-based cancer detection is a new category of tests known as multi-cancer early detection, or MCED, tests. These look for fragments of tumor DNA circulating in your blood, often focusing on specific methylation patterns that differ between cancerous and normal tissue. Unlike a CBC or metabolic panel, these tests are explicitly designed to find cancer.
Early results are promising but imperfect. One test targeting four cancer types (lung, breast, colorectal, and prostate) achieved an overall sensitivity of about 60% with roughly 87% specificity, meaning it correctly identified about six in ten people who had cancer while incorrectly flagging about 13 out of 100 people who did not.13PubMed. Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test Sensitivity varied considerably by cancer type, performing best for lung cancer and worst for breast and prostate. A systematic review of MCED tests found a consistent pattern across studies: sensitivity was lower for early-stage cancers compared to later-stage ones.14PubMed Central. Multi-cancer early detection tests for general population screening: a systematic literature review That is a fundamental tension. The whole point of early detection is catching cancer when it is small, but small tumors shed less DNA into the blood, making them harder to find.
Some MCED tests also attempt to identify where in the body the cancer originated, which is useful for directing follow-up testing. Researchers working on colorectal and gastric cancer detection, for example, have identified specific methylation markers that help distinguish between cancer types and pinpoint the tissue of origin.15PubMed Central. Cell-free DNA methylation profiles enable early detection of colorectal and gastric cancer Without that ability, a positive MCED test could trigger an extensive and expensive search through the entire body to find the cancer’s location.
The Cost Question
MCED tests are not cheap, with current prices in the range of several hundred to nearly a thousand dollars, and they are generally not covered by insurance. A US modeling study estimated that at a price of about $950 per test, MCED testing on top of usual care would cost roughly $66,000 per quality-adjusted life-year gained, which falls below the $100,000 threshold commonly used to define cost-effective interventions in the United States.16The American Journal of Managed Care. Cost-Effectiveness of a Multicancer Early Detection Test in the US The analysis also found that testing was most cost-effective in people at higher genetic risk for cancer, such as those with Lynch syndrome.17Cancer Epidemiology, Biomarkers & Prevention. Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
However, a Canadian analysis of the same general approach reached a very different conclusion, finding MCED testing was not cost-effective at a willingness-to-pay threshold of $100,000 Canadian per quality-adjusted life-year. The model was most sensitive to the cost of the test itself and the specificity of both the MCED test and existing screening for colorectal cancer.18PubMed. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada These conflicting findings reflect genuine uncertainty. Whether MCED testing makes economic sense depends heavily on the price of the test, the healthcare system it sits within, and the population being screened.
The Problem with False Positives
Any test that flags cancer when there is none carries real consequences. False-positive results from cancer screening consistently reduce people’s quality of life in the short term, with measurable impacts on emotional well-being across multiple cancer types.19PubMed Central. Health State Utilities Associated with False-Positive Cancer Screening Results Research on ovarian cancer screening illustrates how this plays out psychologically: about a quarter of women who received a false-positive result experienced high levels of cancer-specific distress that, while declining over time, remained elevated even four months later. Women with a family history of the cancer or lower baseline optimism were most vulnerable.20PubMed Central. Psychological Response to a False Positive Ovarian Cancer Screening Test Result: Distinct Distress Trajectories and Their Associated Characteristics
With MCED tests, a false positive creates an especially complicated situation. A positive result from a test that scans for dozens of cancer types but cannot definitively locate the tumor can send patients on what researchers have called a “diagnostic odyssey,” involving full-body imaging and repeated testing to either find the cancer or rule it out across every organ system.21medRxiv. Assessing potential harms from screening overdiagnosis and false positives with multicancer early detection tests That process is expensive, anxiety-inducing, and can involve its own medical risks. Broader reviews of screening’s psychological effects confirm that the period between learning about an abnormal result and receiving a definitive answer is associated with heightened anxiety and sometimes lingering distress even after clearance.22PubMed Central. The half-painted picture: Reviewing the mental health impacts of cancer screening
Direct-to-Consumer Cancer Screening
You can now buy cancer screening blood tests online without a doctor’s order. This is a rapidly growing market, but it comes with serious caveats. A review of direct-to-consumer screening tests found that virtually all medical tests advertised and sold directly to consumers were not recommended for screening by evidence-based guidelines.23PubMed. Evaluating the evidence: direct-to-consumer screening tests advertised online The concern is not just that the tests may be inaccurate, but that testing healthy people with low disease prevalence leads to a high proportion of falsely abnormal results. An analysis in Clinical Chemistry argued that direct-to-consumer testing offers little to no actual benefit for most consumers and may cause medical, psychological, and financial harm, including unnecessary medicalization of healthy people and strain on healthcare systems when follow-up costs are shifted to public insurance.24Clinical Chemistry. Direct-to-Consumer Testing: Benefits and Concerns of Commercially Accessed Laboratory Tests
If you are considering purchasing a cancer screening blood test on your own, the most important thing to understand is that an abnormal result does not mean you have cancer, and a normal result does not mean you are in the clear. Without a doctor to interpret the result in the context of your full medical history, symptoms, and risk factors, you are left trying to make sense of a number that was never designed to give a definitive answer.
Machine Learning and the Future of Routine Blood Work
Perhaps the most interesting frontier is not new blood tests but new ways of reading the old ones. Several research groups are building machine learning models that analyze patterns across routine blood test results to estimate cancer risk. One study on chronic myelogenous leukemia found that machine learning models trained on standard blood counts could predict the diagnosis with reasonable accuracy, and that some predictive signal existed in blood work collected two to five years before diagnosis.25PubMed Central. BLOod Test Trend for cancEr Detection (BLOTTED): protocol for an observational and prediction model development study using English primary care electronic health record data 26American Journal of Clinical Pathology. A Machine Learning Model to Successfully Predict Future Diagnosis of Chronic Myelogenous Leukemia With Retrospective Electronic Health Records Data Performance improved substantially as the blood counts got closer to the actual diagnosis date, which makes intuitive sense since the disease becomes more biologically pronounced over time.
Similar work is being done for lung cancer, combining routine blood count features with traditional tumor markers to build screening models.27PubMed Central. Development and validation of machine learning models based on blood routine tests and tumor markers in early screening of primary bronchogenic lung cancer For breast cancer, researchers have explored whether CBC-derived ratios could distinguish between women with and without the disease, finding that several blood parameters differed between the two groups but that no single measure was strong enough to serve as a standalone screening tool.28Scientific Reports. Unlocking the complete blood count as a risk stratification tool for breast cancer using machine learning: a large scale retrospective study
These approaches are not ready for clinical use yet, and they may never replace dedicated cancer screening methods like colonoscopy or mammography. But the concept is appealing: if algorithms could reliably flag people at elevated cancer risk using blood tests they are already getting, it could help prioritize who needs more intensive screening without adding any new tests or costs to the annual checkup. It is a space worth watching, even if we are years away from anything your doctor could act on.
Protein Electrophoresis and Blood Cancers
One blood test that does directly screen for a specific cancer category is serum protein electrophoresis, or SPEP. This test separates your blood proteins by size and charge to look for abnormal “M-spikes” produced by cancerous or pre-cancerous plasma cells. It is not part of standard yearly blood work for most people but is sometimes ordered when a doctor suspects myeloma or related conditions based on symptoms like unexplained bone pain, kidney problems, or anemia.
Newer mass spectrometry-based methods are proving substantially more sensitive than traditional SPEP. In a review of nearly 20,000 specimens, the older SPEP method detected M-spikes in about 7% of samples, but the newer approach found additional abnormal proteins in roughly 30% of all samples, identifying M-proteins that were too small for SPEP to quantify.29PubMed. Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases Whether detecting these very small abnormalities leads to better outcomes is still being studied. Many people with a small M-protein will never develop full-blown myeloma, which raises familiar questions about overdiagnosis.